The Middle East & Africa uterine cancer therapeutics & diagnostics market was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 5.7% during 2023–2031. The growth of the market is attributed to rising awareness about uterine disease and increasing number of therapies for the same.
Uterine cancer is also known as womb cancer. Endometrial cancer and uterine sarcoma are two types of cancer that develops from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus and uterine sarcoma forms from the muscles or support tissue of the uterus. Symptoms of endometrial cancer is unusual vaginal bleeding or pelvis pain, while uterine sarcoma symptoms include vaginal bleeding or a lump in the vagina.
The cancer association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer. The mission aims to provide research grants, educating public regarding symptoms, screening and risk reduction, and providing care and support to patients affected by cancer. The department of health in South Africa implemented programs to improve the health of women. Thus, such programs are anticipated to increase early diagnosis procedures.
Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Trends, Drivers, Restraints, and Opportunities
-
Increasing healthcare expenditure in drug development is expected to drive the market growth.
-
Ongoing technological advancements in medical devices is anticipated to positively impact the market growth.
-
Increasing obesity among women in the region can market growth.
-
Adverse effect of the treatment and high toxicity of drugs can hinder the market.
-
Rising innovation in drug development process is expected to create lucrative opportunities for industry players in the projected timeline.
Scope of Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Report
The report on the Middle East & Africa uterine cancer therapeutics & diagnostics market research report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Types of Cancers (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Product (Therapeutics [Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and others] and Diagnostics [Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, and CT Scan]
|
|
Regional Scope
|
GCC, South Africa, and Rest of Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd
|
Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Segment Insights
Endometrial adenocarcinoma segment to account a considerable market share
Based on types of cancers, the market is divided into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. The endometrial adenocarcinoma segment is anticipated to account for a considerable market share during the forecast period. Increasing obesity in women is a primary factor responsible for the growing incidence of the endometrium carcinoma. Moreover, rising awareness about the cancer is excepted to drive the growth of the market segment. Endometrial cancer produces symptoms at early stages, which in turn, helps the patients to diagnose the cancer at early stage.
Chemotherapy segment to account a major market share
Based on products, the market is segregated into therapeutics and diagnostics. The therapeutics segment is further segmented into surgery, immunotherapy, radiation therapy, chemotherapy, and others. The diagnostic segment is classified as biopsy, pelvic ultrasound, hysteroscopy, dilation and curettage, and CT Scan. The chemotherapy segment is expected to hold a major market share owing to the lesser number of drugs approved for the treatment of endometrial cancer. This segment is expected to boost due to the high adoption rate of chemotherapy as compared to radiation and surgical treatment. The chemotherapeutic agents such as carboplatin and paclitaxel are recommended as the first line of therapy in the majority of the cancer cases, which is propelling the demand for these drugs.
The market in South Africa to grow at a rapid pace
In terms of geographies, the market is categorized as GCC, South Africa, and Rest of Middle East & Africa. The market in South Africa is anticipated to exhibit a high CAGR during the forecast period. Increasing prevalence of endometrial cancer, rising awareness about the early diagnosis of cancer, and the presence of the developed healthcare infrastructure are some of the key factors propelling the market growth in the country.
Segments
The Middle East & Africa uterine cancer therapeutics & diagnostics market has been segmented on the basis of
Types of Cancers
- Endometrial Adenocarcinoma
- Adenosquamous Carcinoma
- Papillary Serous Carcinoma
- Uterine Sarcoma
- Others
Products
- Therapeutics
- Surgery
- Immunotherapy
- Radiation Therapy
- Chemotherapy
- Others
- Diagnostics
- Biopsy
- Pelvic Ultrasound
- Hysteroscopy
- Dilation and Curettage
- CT Scan
Geographies
- GCC
- South Africa
- Rest of Middle East & Africa
Key Players
- Abbott Laboratories
- Merck & Co., Inc
- Takeda Pharmaceutical Company Limited
- Siemens Healthcare Inc
- F.Hoffmann-La Roche Ltd
Competitive Landscape
Key players operating in the Middle East & Africa uterine cancer therapeutics & diagnostics market includes Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd.
Request For Customization
Enquiry Before Buying
Speak With Analyst
